Sunday, June 23, 2024
HomeLatest Pharma-NewsArdelyx's kidney disease drug succeeded in regulating elevated blood phosphate levels in...

Ardelyx’s kidney disease drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease (CKD)

Dec 04, 2019, Ardelyx lnc said about its experimental drug succeeded in regulating elevated blood phosphate levels in patients with chronic kidney disease (CKD) in a late-stage study.

As per reports, tenapanor showed a greater difference in serum phosphorus levels compared to placebo.

- Advertisement -

Approx 70% of CKD patients on dialysis continue to experience elevated phosphorus levels, also called hyperphosphatemia , at any point in time, the company said despite treatment with phosphate binders.

Iin September Ardelyx said that in another late-stage study patients treated with tenapanor and phosphate binders, the only approved therapy for hyperphosphatemia, showed a significant reduction in serum phosphorus levels compared to phosphate binders alone.

Tenapanor if approved will be the only non-binder treatment for high serum phosphorus levels in patients with chronic kidney disease on dialysis.
https://ardelyx.com/what-we-do/

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular